CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Belumosudil 200 mg QD +2 moredrug
Likely dose
Belumosudil 200 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05305989
NCT05305989Phase 2Completed
CompareCT.gov

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Kadmon, a Sanofi Company·interventional·Posted Mar 31, 2022·Updated May 2, 2025

In Brief

A Phase 2 clinical trial evaluating Belumosudil 200 mg QD, Belumosudil 200 mg BID, and 1 other intervention for Chronic Graft-versus-host-disease. Completed, enrolled 23 participants across 8 sites.

Detailed Summary

Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft-versus-host-disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 31, 2022
Enrollment StartFeb 23, 2022
Primary CompletionJun 6, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.3 years ago

Interventions

Belumosudil 200 mg QDdrug

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Belumosudil 200 mg BIDdrug

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Belumosudil 400 mg QDdrug

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.